Welcome to our dedicated page for Arcturus Therapeutics Holdings news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings stock.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), founded in 2013 and based in San Diego, California, is a pioneering RNA medicines company focused on developing novel therapeutics for rare diseases, particularly those with no adequate treatments. Specializing in RNA interference (RNAi) technologies, Arcturus is at the forefront of creating breakthrough treatments aimed at liver and respiratory diseases.
Arcturus operates primarily in the research and development sector, focusing on nucleic acid-based medical applications. Core technologies include its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA), enabling a versatile range of RNA therapeutics. Its mRNA drug substance and product manufacturing expertise further position Arcturus as a leader in RNA-based solutions.
Key projects in Arcturus' pipeline include:
- LUNAR-OTC for treating ornithine transcarbamylase deficiency
- LUNAR-CF aimed at cystic fibrosis
- LUNAR-FLU and LUNAR-COV19 for influenza and COVID-19 vaccines respectively
Recently, Arcturus announced a collaborative research endeavor with PassPort Technologies Inc. (PPTI) to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics. This partnership leverages ARCT’s LUNAR® platform and PPTI’s PassPort® transdermal technology, aiming to enhance the delivery and efficacy of RNA-based treatments.
Further cementing its competitive edge, Arcturus has developed Kostaive®, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine. Arcturus continues its global collaboration with CSL Seqirus for mRNA vaccines and maintains a joint venture in Japan, ARCALIS, to manufacture mRNA vaccines and therapeutics. The company’s extensive patent portfolio, covering over 400 patents across the U.S., Europe, Japan, China, and other countries, underscores its innovative prowess.
Financially, Arcturus maintains a solid growth trajectory, driven by its robust research initiatives and strategic alliances. For more detailed information, visit their official website at www.ArcturusRx.com, and connect via Twitter and LinkedIn.
Arcturus Therapeutics Holdings (NASDAQ: ARCT) announced plans for an underwritten public offering of its common stock, with all shares to be sold by the Company. Subject to market conditions, the offering includes a potential 15% overallotment option for underwriters. Proceeds will fund clinical trials and manufacturing of the LUNAR-COV19 vaccine candidate. The offering is registered under an effective SEC shelf, with a prospectus to follow. Piper Sandler & Co. and Guggenheim Securities are joint bookrunners.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has commenced dosing in its Phase 1b clinical trial of ARCT-810 for Ornithine Transcarbamylase (OTC) deficiency, a rare and serious disorder. The study, involving 12 patients, will assess safety, tolerability, and pharmacokinetics at doses ranging from 0.2 mg/kg to 0.4 mg/kg. Previous studies indicated ARCT-810 was safe and well tolerated in healthy subjects, showing a favorable pharmacokinetic profile. OTC deficiency, affecting around 10,000 people worldwide, currently lacks FDA-approved treatments. Arcturus aims to leverage its mRNA platform to address this unmet medical need.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in Piper Sandler’s 32nd Annual Virtual Healthcare Conference, scheduled for December 1, 2020, at 10:00 a.m. ET. The company will present on The Road Ahead for COVID-19 Vaccines. Founded in 2013 and based in San Diego, Arcturus focuses on mRNA medicines and vaccines, including programs targeting COVID-19 and other diseases. The company has developed significant partnerships and holds a robust patent portfolio of 200 patents worldwide, aimed at advancing RNA therapeutic technologies.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) reported its financial results for Q3 2020, with revenues of $2.3 million, a decrease from $3.3 million in Q3 2019. Operating expenses surged to $23.3 million, primarily due to increased spending on clinical trials for ARCT-021 and ARCT-810, leading to a net loss of $21.0 million, or $0.92 per share. Despite the losses, the company’s cash position improved to $307.1 million, bolstered by equity offerings. The ARCT-021 COVID-19 vaccine candidate shows promising preliminary results, and the ARCT-810 candidate for OTC deficiency is advancing into further studies.
Arcturus Therapeutics (Nasdaq: ARCT) reported positive interim results from its Phase 1/2 study of ARCT-021, a COVID-19 vaccine candidate. Conducted in Singapore, the trial enrolled 106 subjects, revealing robust anti-spike protein IgG immune responses across multiple doses. The vaccine was well tolerated, showing a favorable safety profile. Additionally, Arcturus secured a financial commitment of up to $220 million from Singapore's Economic Development Board (EDB) to support vaccine manufacturing, including a $45 million loan linked to future sales.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced its participation in several upcoming investor and scientific conferences. The company will present at the International mRNA Health Conference on November 10, 2020, at 1:40 p.m. ET, and at the Stifel Healthcare Conference on November 17, 2020, at 3:20 p.m. ET. Additionally, Arcturus will engage in a fireside chat at the Piper Sandler Healthcare Conference on November 23, 2020, at 10:00 a.m. ET. The company focuses on mRNA medicines and vaccines for infectious diseases and rare diseases.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the quarter and nine months ended September 30, 2020, after market close on November 9, 2020. A conference call and webcast will be held at 4:30 PM ET on the same day to discuss the results and provide a corporate overview. The company specializes in mRNA medicines, focusing on vaccines for infectious diseases and rare diseases of the liver and respiratory system. Founded in 2013, Arcturus has developed a pipeline that includes self-replicating mRNA vaccine candidates for COVID-19 and influenza.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has completed the first three dose escalation cohorts in its Phase 1 study of ARCT-810, an mRNA-based therapeutic for Ornithine Transcarbamylase (OTC) deficiency. The trial is randomized, double-blind, and placebo-controlled, evaluating safety, tolerability, and pharmacokinetics. Preliminary results show good tolerability and a favorable pharmacokinetic profile. The fourth cohort is expected to complete this quarter, with final results to be reported soon. The company plans to initiate a second clinical study in patients with OTC deficiency this quarter.
Arcturus Therapeutics Holdings announced preclinical results for its vaccine LUNAR®-COV19 (ARCT-021), showing a strong antibody response and 100% protection against SARS-CoV-2 following a single dose vaccination in mice. The study indicates robust neutralizing antibody titers persisting up to day 60, along with significant T cell responses. The clinical study is on track with results expected in Q4 2020. Collaboration with Duke-NUS Medical School enhances credibility, and the company emphasizes the potential of its low-dose, single-shot vaccine approach for COVID-19 mass vaccination.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the successful dosing of all subjects in the first cohort of its Phase 1/2 clinical study for ARCT-021, a self-replicating mRNA vaccine for COVID-19. The study aims to evaluate safety and immunogenicity in younger adults, with clinical data expected in Q4 2020. Preclinical results demonstrated 100% seroconversion after a single low-dose administration, indicating promising efficacy. The vaccine is designed for low-dose, single administration, potentially facilitating mass vaccination efforts against COVID-19.
FAQ
What is the current stock price of Arcturus Therapeutics Holdings (ARCT)?
What is the market cap of Arcturus Therapeutics Holdings (ARCT)?
What does Arcturus Therapeutics specialize in?
What are the core technologies of Arcturus Therapeutics?
What kind of diseases is Arcturus targeting with its therapies?
What recent collaborations has Arcturus entered into?
What is Kostaive®?
Who are Arcturus' major partners?
What is LUNAR-OTC?
How extensive is Arcturus' patent portfolio?
Where is Arcturus Therapeutics headquartered?
How can I get more information about Arcturus Therapeutics?
